PTO/SB/30 (09-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Request	Application Number	09/840,795
For OIPE	Filing Date	April 23, 2001
Continued Examination (RCE)	First Named Inventor	Erin E. MURPHY
Address to: MS RCE Commissioner for Patents P.O. Box 1450		1646
	Art Unit	
Alexandria, VA 22313-1450	Examiner Name	E. O'Hara
	Attorney Docket Number	140942000401
This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.  Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application.		
1. Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and		
amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).		
a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.		
i. Consider the arguments in the Appeal Brief or Reply Brief previously filed on		
ii. Other		
b. x Enclosed		
i. X Amendment/Reply (7 pages) iii. Information Disclosure Statement (IDS)		
Fee Transmittal (1 page + duplicate); Exhibit A (38 pages);  X Petition for Extension of time (1 page); Return receipt  ii. Affidavit(s)/Declaration(s) iv. Other Postcard		
2. Miscellaneous		
a. Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a		
period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)		
b. Other		
3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.		
a. X The Director is hereby authorized to charge the following fees, or credit any overpayments, to		
Deposit Account No. 03-1952		
i. X RCE fee required under 37 CFR 1.17(e)		
ii. X Extension of time fee (37 CFR 1.136 and 1.17) iii. Other		
b. Check in the amount of \$ enclosed		
c. Payment by credit card (Form PTO-2038 enclosed)		
SIGNATYRE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED		
Name (Print/Type) Laurie-1/. Hill	Registration No. (Attorr	ney/Agent) 51,804
Signature / Jumi	Date	September 9, 2004
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 419117038 US,		
in an envelope addressed to: MS RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.		
Dated: September 9, 2004 Signature: Lluff (Cecilia Huerta)		

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 419117038 US, in an envelope addressed to: MS RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date

shown below.

SEP 0 9 2004

Dated: September 9, 2004

Signature: Clerk Huerta)

Docket No.: 140942000401 Client Ref. No. SF0818KQ

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Erin E. MURPHY et al.

Application No.: 09/840,795

Art Unit: 1646

Filed: April 23, 2001

Examiner: E. O'Hara

For: BINDING COMPOUNDS FOR A RANK-LIKE

PROTEIN (AS AMENDED)

## PRELIMINARY AMENDMENT

MS RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This amendment is submitted following the filing of the request for continued examination and in response to the Office Action dated March 9, 2004 and the Advisory Action dated June 21, 2004. Careful consideration has been given to the grounds for rejection as contained in the Office Action, and the enclosed amendments and discussion are offered in response.

Applicants now respectfully request entry and consideration of the arguments presented herein prior to issuance of an action on the merits.

Also included herein is the following Exhibit:

Exhibit A: Sinha et al., J. Biol. Chem. 10.1074/jbc.M407363200 (Jul 2004).